“But AbbVie used legally questionable tactics to block lower-priced biosimilars from reaching American consumers until at least 2023,” Maloney said.
“But AbbVie used legally questionable tactics to block lower-priced biosimilars from reaching American consumers until at least 2023,” Maloney said.